Featured Story

Charles River to Acquire HemaCare

HemaCare logo

We are pleased to announce plans to acquire HemaCare, a leader in the production of human-derived cellular products for the cell therapy market. This acquisition will expand Charles River’s scientific capabilities in the high-growth cell therapy market and establish a comprehensive cell therapy solution from discovery through commercialization.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “Cell and gene therapies are important new modalities, with an estimated 10 to 20 new product approvals per year within five years. In order to continue to enhance our ability to support our clients’ research efforts, particularly in biologics discovery and development, we are expanding our scientific capabilities in this emerging, high-growth market with the acquisition of HemaCare. HemaCare advances the development of life-saving cell therapies through the use of its high-quality cellular products that represent critical inputs to these therapeutics. The addition of HemaCare’s innovative cell therapy products and services to our integrated, early-stage solutions will create a unique, go-to partner for clients to work with Charles River across a comprehensive cell therapy portfolio from idea to novel therapeutic.”

Read the full press release